Technology-based therapy-response and prognostic biomarkers in a prospective study of a de novo Parkinson’s disease cohort
Abstract Early noninvasive reliable biomarkers are among the major unmet needs in Parkinson’s disease (PD) to monitor therapy response and disease progression. Objective measures of motor performances could allow phenotyping of subtle, undetectable, early stage motor impairments of PD patients. This...
Guardado en:
Autores principales: | Giulia Di Lazzaro, Mariachiara Ricci, Giovanni Saggio, Giovanni Costantini, Tommaso Schirinzi, Mohammad Alwardat, Luca Pietrosanti, Martina Patera, Simona Scalise, Franco Giannini, Antonio Pisani |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/36fff3116f8a4b8fbf7c31657fbfb239 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Blunting neuroinflammation with resolvin D1 prevents early pathology in a rat model of Parkinson’s disease
por: Paraskevi Krashia, et al.
Publicado: (2019) -
Author Correction: Blunting neuroinflammation with resolvin D1 prevents early pathology in a rat model of Parkinson’s disease
por: Paraskevi Krashia, et al.
Publicado: (2019) -
Prognostic biomarkers of Parkinson’s disease in the Spanish EPIC cohort: a multiplatform metabolomics approach
por: Carolina Gonzalez-Riano, et al.
Publicado: (2021) -
Distinct patterns of speech disorder in early-onset and late-onset de-novo Parkinson’s disease
por: Jan Rusz, et al.
Publicado: (2021) -
Publisher Correction: Parkinson’s disease prognostic scores for progression of cognitive decline
por: Galina Gramotnev, et al.
Publicado: (2021)